Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases (Q28199775)

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

Europe PubMed Central

title

Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases (English)

0 references

author name string

James M Scheiman

series ordinal

1

0 references

language of work or name

English

0 references

publication date

2006

0 references

published in

Drugs

0 references

volume

66 Suppl 1

0 references

page(s)

15-21; discussion 29-33

0 references

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666001-00004

Prophylactic aspirin and risk of peptic ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666001-00004

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666001-00004

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666001-00004

Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666001-00004

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666001-00004

Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

12 December 2020

Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis

1 reference

12 December 2020

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

12 December 2020

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

12 December 2020

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

12 December 2020

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

12 December 2020

Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users

1 reference

12 December 2020

Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen

1 reference

12 December 2020

National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation

1 reference

12 December 2020

The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis

1 reference

12 December 2020

Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs

1 reference

12 December 2020

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

1 reference

12 December 2020

Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors

1 reference

12 December 2020

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

1 reference

12 December 2020

Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs

1 reference

12 December 2020

Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System

1 reference

12 December 2020

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

1 reference

12 December 2020

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial

1 reference

12 December 2020

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

12 December 2020

Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.

1 reference

12 December 2020

Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen

1 reference

12 December 2020

Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors

1 reference

12 December 2020

Gastroduodenal Safety of Cyclooxygenase-2 Inhibitors

1 reference

12 December 2020

Dyspepsia in NSAID users: the size of the problem

1 reference

12 December 2020

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial

1 reference

12 December 2020

NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2

1 reference

12 December 2020

Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury

1 reference

12 December 2020

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

The time to onset and overall analgesic efficacy of rofecoxib 50 mg: a meta-analysis of 13 randomized clinical trials

1 reference

12 December 2020

Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study

1 reference

12 December 2020